Key result
Blocking Smad phosphorylation blunts aortic myofibroblast transdifferentiation by suppressing RhoGDI-RhoGTPase signaling.
Why the study?
The study was designed to investigate the effects of the Smad pathway on TGFβ1-mediated RhoGDI expression and its binding to RhoGTPases in myofibroblast transdifferentiation.
p-value: p=<0.05
TGFβ1 promotes myofibroblast transdifferentiation in human aortic adventitial fibroblasts via Smad-mediated upregulation of RhoGDI2 and its interaction with RhoGTPases, highlighting a mechanism of vascular remodeling.
In vitro Smad-RhoGDI findings in myofibroblast differentiation are hypothesis-generating; in vivo validation required before any translational relevance.
This study serves to investigate the effects of the Smad pathway on TGFβ1-mediated RhoGDI expression and its binding to RhoGTPases in myofibroblast transdifferentiation. Myofibroblast transdifferentiation was induced by TGFβ1 in vitro. Cells were pretreated with different siRNAs or inhibitors. Myofibroblast transdifferentiation was detected by immunohistochemistry. Immunofluorescence was used to observe the nuclear translocation of Smad4, and PSR (Picrositius Red) staining was used to measure collagen concentration. TGFβ1 induced the phosphorylation of Smad2/3 and the nuclear translocation of Smad4 in human aortic adventitial fibroblasts (HAAFs). Furthermore, TGFβ1 increased the expression of RhoGDI and its binding to RhoGTPases. Nevertheless, inhibition of Smad2/3 phosphorylation decreased TGFβ1-induced RhoGDI1/2 expressions and RhoGDI2-RhoGTPases interactions. These data suggested that the inhibition of Smad phosphorylation attenuates myofibroblast transdifferentiation by inhibiting TGFβ1-induced RhoGDI1/2 expressions and RhoGDI-RhoGTPases signaling.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2022) studied Myofibroblast transdifferentiation. TGFβ1 and SB505124 (Smad2/3 inhibitor) vs. Untreated cells was evaluated on Myofibroblast transdifferentiation (α-SMA expression and collagen secretion) and RhoGDI-RhoGTPase signaling (p=<0.05). Inhibition of Smad phosphorylation attenuates myofibroblast transdifferentiation by inhibiting TGFβ1-induced RhoGDI1/2 expressions and RhoGDI-RhoGTPases signaling in human aortic adventitial fibroblasts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: